CLARITY - Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-Remitting MS - Contacts and Locations

Home

CLARITY - Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-Remitting MS

This study is ongoing, but not recruiting participants.

Study NCT00213135. Last updated on September 29, 2008. Information provided by EMD Serono

Please refer to this study by its ClinicalTrials.gov identifier: NCT00213135

Locations


Switzerland
	Local Medical Information Office
	Geneva, Switzerland

Sponsors and Collaborators

EMD Serono

Investigators


Study Director:	Steven Greenberg, M.D.	EMD Serono, Inc.